Experts from 25 countries will attend an International Congress on the control of diabetes in which the Caribbean country wants to demonstrate the applications of the Heberprot-P drug, used to treat the ulcer of the diabetic foot and avoid amputations.
The International Congress "controlling diabetes and its most severe complications", which will take place from December 5 to 9 in Varaderby the state Cuban news agency.
In this scenario, Cuba will make presentations on Heberprot-P, with which 243,000 people from 23 countries "with very good results have been treated," said Raíces.
In the case of the island, where almost one million people suffer from diabetes, the medicine has been used in more than 55,000 cases and has decreased the relative risk of amputation by diabetic foot ulcers by more than 71 %, he said.
The scientist, a researcher at the Center for Genetic Engineering and Biotechnology (CIGB), recalled that about 422 million people in the world suffer from diabetes and that the disease is attributable to the generalization of "unhealthy lifestyle habits" such as poor diet,sedentary and stress.
He indicated that in the December Congress, forty international experts and about twenty Cubans will participate, including Professor Jorge Berlanga, creator of the drug against the ulcer of the diabetic foot.
Raíces reported that Nations specialists will attend where Heberprot-P is applied with good results, including Russia, Belarus, Algeria, Turkey, Ecuador, Venezuela, Guatemala and Argentina.
The forum will include master conferences, oral presentations and posters, as well as symposia on the prevention, management of diabetes and metabolic control in the patient.
In this call, the first United Cuba-United States symposium for the control of diabetes and another international specifically aimed at the analysis of complex ulcers treated with the Cuban medicine is also framed.
The United States, a country with which Cuba initiated a process of standardization of relations in December 2014, has also shown interest in the therapeutic vaccine against lung cancer "Cimavax EGF", also developed in the CIGB.
That institution signed in April 2015 an agreement with the Roswell Park Institute against New York cancer to export the drug to the USA.
